Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $67.6 million.

  • Xeris Biopharma Holdings' Operating Expenses rose 72.66% to $67.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.3 million, marking a year-over-year increase of 1023.88%. This contributed to the annual value of $236.7 million for FY2024, which is 1384.74% up from last year.
  • Xeris Biopharma Holdings' Operating Expenses amounted to $67.6 million in Q3 2025, which was up 72.66% from $67.1 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Operating Expenses registered a high of $69.7 million during Q4 2021, and its lowest value of $24.9 million during Q1 2021.
  • In the last 5 years, Xeris Biopharma Holdings' Operating Expenses had a median value of $54.0 million in 2023 and averaged $52.6 million.
  • In the last 5 years, Xeris Biopharma Holdings' Operating Expenses skyrocketed by 11488.47% in 2021 and then tumbled by 3068.29% in 2022.
  • Xeris Biopharma Holdings' Operating Expenses (Quarter) stood at $69.7 million in 2021, then crashed by 30.68% to $48.3 million in 2022, then rose by 12.25% to $54.2 million in 2023, then rose by 7.72% to $58.4 million in 2024, then increased by 15.8% to $67.6 million in 2025.
  • Its Operating Expenses stands at $67.6 million for Q3 2025, versus $67.1 million for Q2 2025 and $63.2 million for Q1 2025.